In vitro functional and immunomodulatory properties of the Lactobacillus helveticus MIMLh5-Streptococcus salivarius ST3 association that are relevant to the development of a pharyngeal probiotic product
- PMID: 22504812
- PMCID: PMC3370528
- DOI: 10.1128/AEM.00325-12
In vitro functional and immunomodulatory properties of the Lactobacillus helveticus MIMLh5-Streptococcus salivarius ST3 association that are relevant to the development of a pharyngeal probiotic product
Abstract
The use of proper bacterial strains as probiotics for the pharyngeal mucosa is a potential prophylactic strategy for upper respiratory tract infections. In this context, we characterized in vitro the functional and immunomodulatory properties of the strains Lactobacillus helveticus MIMLh5 and Streptococcus salivarius ST3 that were selected during previous investigations as promising pharyngeal probiotics. In this study, we demonstrated in vitro that strains MIMLh5 and ST3, alone and in combination, can efficiently adhere to pharyngeal epithelial cells, antagonize Streptococcus pyogenes, and modulate host innate immunity by inducing potentially protective effects. In particular, we found that the strains MIMLh5 and ST3 activate U937 human macrophages by significantly inducing the expression of the proinflammatory cytokine tumor necrosis factor alpha (TNF-α). Nonetheless, the induction of the anti-inflammatory interleukin-10 (IL-10) by MIMLh5 or ST3 was never lower than that of TNF-α, suggesting that these bacteria can potentially exert a regulatory rather than a proinflammatory effect. We also found that the strains MIMLh5 and ST3 induce cyclooxygenase 2 (COX-2) expression and demonstrated that toll-like receptor 2 (TLR-2) participates in the recognition of the strains MIMLh5 and ST3 by U937 cells. Finally, we observed that these microorganisms grow efficiently when cocultured in milk, suggesting that the preparation of a milk-based fermented product containing both MIMLh5 and ST3 can be a practical solution for the administration of these bacteria. In conclusion, we propose the combined use of L. helveticus MIMLh5 and S. salivarius ST3 for the preparation of novel products that display probiotic properties for the pharyngeal mucosa.
Figures
Similar articles
-
A dairy bacterium displays in vitro probiotic properties for the pharyngeal mucosa by antagonizing group A streptococci and modulating the immune response.Infect Immun. 2010 Nov;78(11):4734-43. doi: 10.1128/IAI.00559-10. Epub 2010 Aug 23. Infect Immun. 2010. PMID: 20732995 Free PMC article.
-
S-layer protein mediates the stimulatory effect of Lactobacillus helveticus MIMLh5 on innate immunity.Appl Environ Microbiol. 2013 Feb;79(4):1221-31. doi: 10.1128/AEM.03056-12. Epub 2012 Dec 7. Appl Environ Microbiol. 2013. PMID: 23220964 Free PMC article.
-
Oral bacteria as potential probiotics for the pharyngeal mucosa.Appl Environ Microbiol. 2010 Jun;76(12):3948-58. doi: 10.1128/AEM.00109-10. Epub 2010 Apr 23. Appl Environ Microbiol. 2010. PMID: 20418429 Free PMC article.
-
A comprehensive post-market review of studies on a probiotic product containing Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011.Benef Microbes. 2011 Dec 1;2(4):319-34. doi: 10.3920/BM2011.0032. Benef Microbes. 2011. PMID: 22146691 Review.
-
Probiotic properties of Lactobacillus salivarius and closely related Lactobacillus species.Future Microbiol. 2010 May;5(5):759-74. doi: 10.2217/fmb.10.35. Future Microbiol. 2010. PMID: 20441548 Review.
Cited by
-
The vaginal isolate Lactobacillus paracasei LPC-S01 (DSM 26760) is suitable for oral administration.Front Microbiol. 2015 Sep 15;6:952. doi: 10.3389/fmicb.2015.00952. eCollection 2015. Front Microbiol. 2015. PMID: 26441886 Free PMC article.
-
Impact of kefir derived Lactobacillus kefiri on the mucosal immune response and gut microbiota.J Immunol Res. 2015;2015:361604. doi: 10.1155/2015/361604. Epub 2015 Feb 24. J Immunol Res. 2015. PMID: 25811034 Free PMC article.
-
Otitis media among high-risk populations: can probiotics inhibit Streptococcus pneumoniae colonisation and the risk of disease?Eur J Clin Microbiol Infect Dis. 2013 Sep;32(9):1101-10. doi: 10.1007/s10096-013-1858-0. Epub 2013 Mar 20. Eur J Clin Microbiol Infect Dis. 2013. PMID: 23512465 Review.
-
A mix of chlorogenic and caffeic acid reduces C/EBPß and PPAR-γ1 levels and counteracts lipid accumulation in macrophages.Eur J Nutr. 2022 Mar;61(2):1003-1014. doi: 10.1007/s00394-021-02714-w. Epub 2021 Oct 26. Eur J Nutr. 2022. PMID: 34698900
-
Lactobacillus helveticus MIMLh5-specific antibodies for detection of S-layer protein in Grana Padano protected-designation-of-origin cheese.Appl Environ Microbiol. 2014 Jan;80(2):694-703. doi: 10.1128/AEM.03057-13. Epub 2013 Nov 15. Appl Environ Microbiol. 2014. PMID: 24242242 Free PMC article.
References
-
- Aderem A, Underhill DM. 1999. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 17:593–623 - PubMed
-
- Akira S, Hemmi H. 2003. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85:85–95 - PubMed
-
- Amdekar S, et al. 2011. Lactobacillus casei reduces the inflammatory joint damage associated with collagen-induced arthritis (CIA) by reducing the pro-inflammatory cytokines: Lactobacillus casei: COX-2 inhibitor. J. Clin. Immunol. 31:147–154 - PubMed
-
- Belardelli F. 1995. Role of interferons and other cytokines in the regulation of the immune response. APMIS 103:161–179 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials